Cut costs and accelerate safety assessments with human-relevant in vitro models, AI, organ-on-chip and high-throughput screening amid regulatory and ethical shifts.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "In Vitro Toxicology Testing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global in vitro toxicology testing market was valued at US$14 billion in 2025 and is projected to reach US$27.4 billion by 2032, expanding at a compound annual growth rate
Elliott Investment Management has taken an activist position in Bio-Rad Laboratories (NYSE:BIO), pushing for changes at the diagnostics group. The investor is calling out what it views as hidden value at Bio-Rad, including the company’s stake in Sartorius. Elliott is also urging a review of operations and capital allocation, which could lead to restructuring or asset monetization moves. The new activist pressure from Elliott on Bio-Rad’s operations and Sartorius stake is important, but it...
Bio-Rad Laboratories reported third quarter 2026 sales of US$656.4 million and net income of US$458.6 million, compared with a loss a year earlier, alongside a US$49.8 million impairment of purchased intangibles. The swing from loss to profit, supported by stronger international revenue surprises in Asia and EMEA, highlights how overseas demand is influencing Bio-Rad Laboratories' current earnings mix. The focus now is on how this sharp earnings turnaround at Bio-Rad Laboratories could...
Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Bio-Rad Laboratories (BIO) drew fresh attention after CFO Roop K. Lakkaraju was slated for a fireside chat at the UBS Global Healthcare Conference, a forum investors often watch for management commentary. Recent trading tells a mixed story for Bio-Rad Laboratories. The share price is US$372.18 after a 1-day share price return that declined 3.18%. However, the 90-day share price return of 14.35% and year-to-date share price return of 21.92% point to momentum that has been building over the...
Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "South & Central America Point of Care Diagnostics Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis" has been added to ResearchAndMarkets.com's offering. The South & Central America point of care (POC) diagnostics market is projected to reach US$ 6,924.0 million by 2031, rising from US$ 3,508.9 million in 2024. According to the report, the market is expected to record a compound annual growth rate (CAGR) of 1
Boost ROI with real-time analytics, advanced spectroscopy and PAT to optimize yields, cut waste, prevent batch failures and strengthen process safety.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Reaction Monitoring - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering The global reaction monitoring market, valued at US$1.6 billion in 2024, is projected to reach US$2 billion by 2030, expanding at a compound annual growth rate (CAGR) of 4.1% between 2024 and 2030. M
HERCULES, Calif., October 14, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2026 on Wednesday, November 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.
Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions. Speaking at a Bernstein conference, Chief Financial Offic
Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.
Opportunities include automated closed systems, AI-enabled quality control, single-cell and cell therapy workflows, precision medicine, advanced diagnostics and emerging-market expansion.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Cell Isolation/Cell Separation Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The market research report examines the global Cell Isolation/Cell Separation Market, which is projected to reach USD 6.97 billion in 2026 and grow a
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
Demand is rising for real-time biomolecular analysis in drug discovery and diagnostics, driven by SPR/BLI advances, automation, high-throughput screening and biomarker research.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Label-free Array Systems - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Label-free Array Systems was valued at US$1.8 Billion in 2024 and is projected to reach US$2.4 Billion by 2030, growing at a CAGR of 5.6% from 2
HERCULES, Calif., September 16, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time.
Bio-Rad Laboratories has delivered a sharp mix of outcomes for long term holders, with the stock down about 52.9% over 5 years even as shorter term returns have turned positive. This puts the spotlight on what its current share price implies about the cash the business can generate. With the valuation lens focused on cash flows through a Discounted Cash Flow (DCF) framework, the question is how well today's market price lines up with the stream of money the company may produce for...
HERCULES, Calif., August 31, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo’s 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time).
This is the newest page. Registered accounts read further back.